Goldman Sachs has begun its coverage of Immunovant (IMVT, Financial) once again, assigning the stock a Neutral rating. The investment firm has set a price target of $18. While Goldman Sachs acknowledges that there is limited risk of significant decline for the company's stock, they also point out that Immunovant is facing a tough regulatory environment. This situation presents both challenges and opportunities for the company moving forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Immunovant Inc (IMVT, Financial) is $43.75 with a high estimate of $61.00 and a low estimate of $17.00. The average target implies an upside of 153.04% from the current price of $17.29. More detailed estimate data can be found on the Immunovant Inc (IMVT) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Immunovant Inc's (IMVT, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
